Show simple item record

dc.contributor.authorFernández-Vega B.
dc.contributor.authorNicieza J.
dc.contributor.authorÁlvarez-Barrios A.
dc.contributor.authorÁlvarez L.
dc.contributor.authorGarcía M.
dc.contributor.authorFernández-Vega C.
dc.contributor.authorVega J.A.
dc.contributor.authorGonzález-Iglesias H.
dc.date.accessioned2020-09-02T22:17:32Z
dc.date.available2020-09-02T22:17:32Z
dc.date.issued2020
dc.identifier10.3390/nu12030723
dc.identifier.citation12, 3, -
dc.identifier.issn20726643
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4464
dc.descriptionNutritional supplementation with antioxidants and vitamins is widely recommended in the treatment of vascular disorders affecting the retina, although there is insufficient evidence on its effectiveness. The vitamin-like compound coenzyme Q10 (CoQ10) is a nutritional supplement of current interest to treat neurodegenerative diseases. Here, we report a retrospective clinical case series study of 48 patients diagnosed with retinal vascular diseases, including non-arteritic ischemic optic neuropathy (NAION), retinal artery occlusion (RAO), and homonymous hemianopia or quadrantanopia following stroke, treated with oral supplementation with CoQ10 (100 mg per day) and vitamins. Patient follow-up was performed using the Humphrey field analyzer and 30-2 testing algorithm to determine the visual field index (VFI) and progression rates. All treated patients showed positive VFI progression rates per year: +11.5 ± 15% for NAION patients (n = 18), +22 ± 17% for RAO patients (n = 7), +9.3 ± 10.5% for hemianopia/quadrantanopia patients (n = 10), and +11 ± 21% for patients with other conditions (n = 13). The interruption of CoQ10 supplementation in one patient resulted in a pronounced decrease of the VFI, which was partially recovered when treatment was restored. This study supports the role of CoQ10 as a nutritional therapeutic agent for vascular diseases affecting the retina. Owing to decreased VFI after interruption of CoQ10, its beneficial effects may be reversible. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.language.isoen
dc.publisherMDPI AG
dc.subjectCoenzyme Q10
dc.subjectDietary supplementation
dc.subjectRetina
dc.subjectVascular diseases
dc.subjectVisual field defects
dc.subjectVitamins
dc.subjectascorbic acid
dc.subjectcyanocobalamin
dc.subjectmagnesium
dc.subjectnutrition supplement
dc.subjectpyridoxine
dc.subjectselenium
dc.subjectthiamine
dc.subjectubidecarenone
dc.subjectvitamin
dc.subjectxanthophyll
dc.subjectzeaxanthin
dc.subjectzinc
dc.subjectadult
dc.subjectArticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdiet supplementation
dc.subjectfemale
dc.subjectfollow up
dc.subjecthemianopia
dc.subjecthomonymous hemianopia
dc.subjecthuman
dc.subjectmale
dc.subjectmiddle aged
dc.subjectoptic nerve
dc.subjectoptic nerve atrophy
dc.subjectoptical coherence tomography
dc.subjectretina
dc.subjectretina artery
dc.subjectretina blood vessel occlusion
dc.subjectvascular disease
dc.subjectvision
dc.subjectvisual evoked potential
dc.subjectvisual field
dc.subjectvitamin supplementation
dc.titleThe use of vitamins and coenzyme Q10 for the treatment of vascular occlusion diseases affecting the retina
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record